Day One Biopharmaceuticals, Inc. (DAWN)
Market: NASD |
Currency: USD
Address: 2000 Sierra Point Parkway
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
📈 Day One Biopharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$28.00
-
Upside/Downside from Analyst Target:
336.82%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Day One Biopharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-02-02 (estimated upcoming) | - |
| 2025-10-20 (estimated upcoming) | - |
| 2025-07-08 (estimated upcoming) | - |
| 2025-05-06 | -0.35 |
| 2025-02-25 | -0.64 |
| 2024-10-30 | -0.37 |
| 2024-07-30 | -0.05 |
| 2024-05-06 | -0.72 |
| 2024-02-26 | -0.64 |
| 2023-11-06 | -0.54 |
| 2023-08-07 | -0.61 |
| 2023-05-01 | -0.59 |
| 2023-03-06 | -0.56 |
| 2022-11-07 | -0.53 |
| 2022-08-04 | -0.6 |
| 2022-05-12 | -0.48 |
| 2022-03-07 | -0.36 |
| 2021-11-08 | -0.33 |
| 2021-08-10 | -5.04 |
| 2021-05-27 | - |
📰 Related News & Research
🔍 View more Reports
